Agenus Inc. (AGEN) Stock: BOT+BAL Delivers 21.2-Month Survival in Colorectal Cancer Trial

TLDR BOT+BAL delivers 21.2-month median survival in refractory MSS colorectal cancer. Three-year overall survival reaches 33% in Agenus’ fully enrolled Phase 1b cohort. Confirmed response rate hits 21%, including three complete and 23 partial responses. BOT+BAL responses appear even in tumors with low TMB and no detectable PD-L1. Extended follow-up finds no new safety signals [...]

The post Agenus Inc. (AGEN) Stock: BOT+BAL Delivers 21.2-Month Survival in Colorectal Cancer Trial appeared first on Blockonomi.